ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

Pulmonary Hypertension

Journal: International Journal of Science and Research (IJSR) (Vol.8, No. 2)

Publication Date:

Authors : ;

Page : 776-778

Keywords : Pulmonary Hypertension;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

As I got diagnosed in 2010 with Pulmonary Hypertension most of the time I use to think that if I have some information regarding this disease I would have taken precautions to prevent complications, so that my severity of disease will be controlled or may be delayed. But being a medical professional I was not much aware regarding this disease which leads me to suffer a lot. This is disease is very uncommon. Although Pulmonary Hypertension was discovered in 1891, there were no known treatments for the disease until 1994 when FLOLAN was introduced. Prior to the release of that medication, the prognosis and life expectancy for a patent with Pulmonary Hypertension was around 3 years and it took an average of 2 years to accurately diagnose a patient. Flolan was the first drug to increase the life expectancy by up to 5 years for pulmonary hypertension patients. While we do not currently have a cure for the disease, several more treatments have been approved for PAH thanks to research. Over the past 20 years, we have gone from no medication to treat PAH to over 10 medications. Even more medications are being studied. We are optimistic that our patients will continue to experience longer survival and better quality of life. These data were collected for the most part in the early 2000s as part of the reveal Regisrty and thus do not reflect todays best care. What this data showed us in that in this group of 2, 635 patients, overall one year survival was 85 %, three year survival was 68 %, five year survival was 57 % and seven year survival was 49 %.

Last modified: 2021-06-28 17:24:41